Claims for Patent: 8,273,721

Summary for Patent: 8,273,721

Title:	Combination treatment for bladder cancer
Abstract:	Novel methods useful for treating a patient with bladder cancer such as superficial bladder cancer includes administering to the patient a therapeutically effective amount of valrubicin and trospium chloride.
Inventor(s):	Shipley; James E. (Lexington, MA)
Assignee:	Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA)
Application Number:	12/397,831
Patent Claims:	1. A method of treating a patient suffering from bladder cancer comprising administering to the patient a therapeutically effective amount of valrubicin, trospium chloride, and a mucin degrading enzyme comprising trypsin or hyaluronidase. 2. The method of claim 1 in which said administration of valrubicin and trospium chloride is carried out concomitantly. 3. The method of claim 1 in which said administration of valrubicin and trospium chloride is carried out sequentially. 4. The method of claim 1 in which said administration of valrubicin and trospium chloride is carried out parenterally. 5. The method of claim 1 in which said administration of valrubicin is carried out parenterally. 6. The method of claim 1 in which said administration of trospium chloride is carried out enterally. 7. The method of claim 1 in which said administration of valrubicin is carried out parenterally, and said administration of trospium chloride is carried out enterally. 8. The method of claim 1 in which said valrubicin and trospium chloride are co-administered in a combined dosage form comprising about 5 to 100 mg/mL valrubicin, and about 5 to 100 mg/mL trospium chloride. 9. The method of claim 1 further comprising the step of performing a transurethral resection procedure on the patient prior to the administration step. 10. The method of claim 1 in which said administration step is carried out to a patient suffering from superficial bladder cancer. 11. The method of claim 1 in which said administration step is carried out to a patient suffering from carcinoma in situ of urinary bladder. 12. A pharmaceutical composition comprising a therapeutically effective amount of valrubicin or its pharmaceutically acceptable salt, trospium chloride, a mucin degrading enzyme comprising trypsin or hyaluronidase, and optionally a pharmaceutically acceptable carrier. 13. The pharmaceutical composition of claim 12 which comprising about 5 to 100 mg/mL valrubicin or its pharmaceutically acceptable salt, and about 5 to 100 mg/mL trospium chloride. 14. The method of claim 1, wherein the mucin degrading enzyme comprises trypsin, animal hyaluronidase, or human recombinant hyaluronidase. 15. The method of claim 1, wherein the mucin degrading enzyme comprises trypsin. 16. The pharmaceutical composition of claim 12, wherein the mucin degrading enzyme comprises trypsin, animal hyaluronidase, or human recombinant hyaluronidase. 17. The new pharmaceutical composition of claim 12, wherein the mucin degrading enzyme comprises trypsin. 18. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier comprises saline.

Details for Patent 8,273,721

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2028-03-05
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2028-03-05
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2028-03-05
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2028-03-05
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005		2028-03-05
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	June 22, 2017		2028-03-05